CD8A and neoplasm: Moreover, metabolites such as SCFAs can also help to the improvement of the immune response to oxaliplatin.265 SCFAs, especially butyrate, are able to block histone deacetylases (HDCA) to upregulate the DNA transcription modulator inhibitor of DNA binding 2 (ID2).266 This, in turn, enhances the cytotoxic activity of CD8+ T cells through IL-12 signaling, promoting anti-tumor immunity generated by oxaliplatin.